NeuroMetrix, Inc. (NURO)

Market Cap	7.97M
Revenue (ttm)	3.77M
Net Income (ttm)	-7.68M
Shares Out	2.04M
EPS (ttm)	-4.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,307
Open	4.005
Previous Close	3.900
Day's Range	3.800 - 4.005
52-Week Range	2.660 - 4.730
Beta	2.21
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About NURO

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disp...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: NURO
• Website: https://www.neurometrix.com

Financial Performance

In 2023, NeuroMetrix's revenue was $5.90 million, a decrease of -28.52% compared to the previous year's $8.26 million. Losses were -$6.53 million, 47.8% more than in 2022.